GGrantIndex
← Search

NIDCD Core for Clinical Research and Care

$2,540,955ZIDFY2021DCNIH

National Institute On Deafness And Other Communication Disorders

Investigators

Linked publications & trials

Abstract

The NIDCD Core for Clinical Research and Care supports the following NIDCD projects: 1 Z01-DC-000016 NF-kappaB in the molecular pathogenesis and therapy of Neoplasms Affecting Human Communication 1 ZIA DC000039 Identification of Genes Causing Syndromic And Nonsyndromic Hearing Impairment 1 ZIA DC000046 Genetic Studies of Human Communications Disorders 1 ZIA DC000060 Molecular Analysis Of Human Hereditary Deafness 1 ZIA DC000064 Clinical Analysis Of Disorders Of Hearing And Balance 1 ZIA-DC-000073 Signal and Transcription Factor Network Interactions in Head and Neck Cancer 1 ZIA-DC-000074 Genomics and Proteomics of Head and Neck Cancer 1 ZIA-DC-000082 Neurotology Program 1 ZIA-DC-000087 Characterization & Enhancement of Anti-tumor Immune Responses in Head & Neck Cancer 1-ZIA-DC-000088 Cellular and Molecular Pathogenesis of Hearing Restoration in Adullt Inner Ear 1-ZIA-DC-000090 Mechanisms and Optimal Combination of Cisplatin Chemotherapy for Head and Neck Cancer The NIDCD and collaborative protocols supported by the core include: OH93-DC-0016 - Nonsyndromic Hereditary Hearing Impairment Gene Mapping: India / Pakistan Protocol 97-DC-0180 - Genetic Analysis of Human Hereditary Hearing Impairment 01-DC-0228 - Clinical and Molecular Analysis of Hearing Impairment with Enlarged Vestibular Aqueducts 01-DC-0229- Genetic Analysis of Hereditary Disorders of Hearing and Balance 17-DC-0138 - Cisplatin and statins in ototoxcity 18-DC-0051 - NIDCD Biospecimens protocol 20-DC-0047 Natural History and Genome Editing in Dominant Hearing Loss 21-DC-0002 Phase III Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss 21-C-0009 A Natural History Study of Children and Adults With Olfactory Neuroblastoma 000077 Clinical Data and Specimens in head and neck disorders 000141 Hearing Instability Phenotyping 15-D-0129 Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 in Irradiation-Induced Parotid Salivary Hypofunction 19-C-0041 Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma 19-C-0002 A Phase II Study of M7824 in Subjects with Recurrent Respiratory Papillomatosis 20-C-0024 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination with TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated with Human Papillomavirus Infection 20-C-0155 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetic , Immune and Clinical Activity of SX-682 in Combination with M7824 With CV301 TRICOM in Advanced Solid Tumors 20-C-0104 Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects with HPV Positive Cancers 21-C-0013 A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis The NIDCD Core for Clinical Research and Care supports over 3,000 outpatient clinic evaluations per year. Core otolaryngologists perform 50-100 major surgical cases annually. Staff mentor medical students during senior clinical clerkships. The Otolaryngologist Surgeon Scientist Career Development Program is coordinated through the OCD.

View original record on NIH RePORTER →